EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis

Yuto Yoshinaga, Takahiro Inoue

Health Policy OPEN · 2026-11 · 11 · 100181

DOI: 10.1016/j.hpopen.2026.100181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Policy OPEN, 2026-11. Verfasst von Yuto Yoshinaga und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Accountancy (Accounting School), Graduate School of Economics and Management, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyag…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rising pharmaceutical prices and increasing research and development (R&D) expenditure by pharmaceutical companies have raised concerns about hospital financial sustainability worldwide. Nevertheless, evidence on the association between pharmaceutical-industry R&D expenditure and hospital financial performance remains limited.

Objectives

To examine whether the associations between pharmaceutical-industry R&D expenditure and hospital financial performance differ between the special functioning hospital category, which provides advanced medical care, and other hospital categories.

Methods

This study integrated annual financial data for four institutionally defined hospital categories with firm-level R&D data for listed pharmaceutical companies. Hospital data were obtained from a national survey by Japan's Ministry of Health, Labour and Welfare. Firm-level R&D data from NEEDS-Financial QUEST 2.0, eol, and company disclosures were aggregated into an industry-level measure aligned with the hospitals' fiscal year. Hospital-category fixed-effects models were used in the analyses.

Results

The association between pharmaceutical-industry R&D expenditure and the pharmaceutical cost ratio was more positive for the special functioning hospital category than for the other categories. The association with the medical operating margin was also more negative for this category.

Conclusions

Higher R&D expenditure was associated with less favorable financial indicators for the special functioning hospital category than for the other categories. These findings suggest that hospitals providing advanced medical care may face greater financial pressures related to pharmaceutical R&D and high-cost medicines, although hospital-level evidence is needed to confirm this interpretation.

Schlagwörter

Stichwörter der Autor:innen

Financial performanceFixed effectsHospitalJapanPharmaceutical costR&D

Autor:innen und Institutionen

  • Department of Accountancy (Accounting School), Graduate School of Economics and Management, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi, Japan.
  • Healthcare Management Research Center, Chiba University Hospital, Chiba, Chiba, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Yoshinaga, Y., & Inoue, T. (2026). Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis. Health Policy OPEN, 11, 100181. https://doi.org/10.1016/j.hpopen.2026.100181

Vancouver

Yoshinaga Y, Inoue T. Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis. Health Policy OPEN. 2026;11:100181. doi:10.1016/j.hpopen.2026.100181

BibTeX
@article{Yoshinaga2026,
  author = {Yoshinaga, Yuto and Inoue, Takahiro},
  title = {Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis},
  journal = {Health Policy OPEN},
  year = {2026},
  volume = {11},
  pages = {100181},
  doi = {10.1016/j.hpopen.2026.100181}
}
Kostenlos starten →